Lilly to present data for galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting

Eli Lilly and CompanyEli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017, in Boston.

Lilly will present four abstracts at AAN, including safety and patient outcomes data for galcanezumab in patients with migraine and factors associated with a reduction in monthly migraine headache days among patients with episodic migraine. Lilly will also highlight findings from U.S. healthcare claims data identifying clinical characteristics and treatment patterns among patients with cluster headache.

Galcanezumab is a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of episodic and chronic migraine and cluster headache. Galcanezumab is a monoclonal antibody specifically designed to bind to and inhibit the activity of CGRP that may prevent or significantly reduce the frequency of monthly migraine headache days in patients with episodic and chronic migraine and cluster headache.

"Migraine and cluster headaches are serious, neurological diseases that have a significant physical and emotional impact on not only people affected, but those with whom they interact at home and at work," said Sheena Aurora, M.D., medical fellow and global launch leader, galcanezumab, Eli Lilly and Company. "Lilly is excited to present these galcanezumab data, which further our understanding of these diseases and support our decades-long effort to develop a targeted, preventive therapy that can bring significant value to patients, including a meaningful reduction in the number of days lost to migraine."

Studies, as well as the dates and times of the data sessions, are highlighted below.

Sunday, April 23 - 4:00-5:30 p.m. ET

P1.181: Clinical Characteristics and Treatment Patterns among Patients with Diagnostic Codes for Cluster Headache in the U.S. Healthcare Claims Data
Presenter: Casey Choong, associate consultant, Eli Lilly & Company, Indianapolis, IN

Monday, April 24 - 5:30-7:00 p.m. ET

P2.164: Hepatic Safety of Galcanezumab in Patients with Migraine: Results of Three Phase 2 Double-Blind Placebo-Controlled Trials
Presenter: Vladimir Skljarevski, M.D., medical fellow, Eli Lilly & Company, Indianapolis, IN
P2.177: Factors Associated with Significant Reduction in Migraine Headache Days: A Post-Hoc Analysis of a Phase 2 Placebo-Controlled Trial in Patients Treated with Galcanezumab
Presenter: Sheena Aurora, M.D., medical fellow and global launch leader, galcanezumab, Eli Lilly & Company, Indianapolis, IN
P2.179: Measures of Functioning Using MSQ v2.1 in Patients with a History of Episodic Migraine and Treated with Galcanezumab or Placebo Injections in a Phase 2 Clinical Trial
Presenter: David Ayer, senior research scientist, Eli Lilly & Company, Indianapolis, IN

Top-line results for galcanezumab for the treatment of migraine are expected in 2017. Lilly plans to submit galcanezumab for regulatory approval for migraine in the second half of 2017.

About Galcanezumab
Galcanezumab is a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of episodic and chronic migraine and cluster headache. Galcanezumab is a monoclonal antibody specifically designed to bind to and inhibit the activity of CGRP that may prevent or significantly reduce the frequency of monthly migraine headache days in patients with episodic and chronic migraine.

About Migraine
Migraine is a painful, neurological disease characterized by recurrent episodes of severe headache, and is often accompanied by other symptoms including nausea, vomiting, sensitivity to light and sound, and changes in vision.(1,2) More than 38 million Americans have migraine, with three times more women affected by migraine compared to men.(1,3) According to the Migraine Research Foundation, healthcare and lost productivity costs associated with migraine are estimated to be as high as $36 billion annually in the United States,(1) yet it remains under-recognized and under-treated, with more than 40 percent of people going undiagnosed.(4)

About Cluster Headache
Cluster headache, often characterized as the most painful of all headaches, is a neurological disease characterized by recurrent, severe headaches on one side of the head, usually behind or around one eye.(2,5) Cluster headaches - commonly known as "attacks" - typically last between 15 minutes to more than two hours and can recur on the same day and occur daily to multiple times a day for weeks or longer, followed by periods of time in which no attacks occur.(5) Cluster headache is classified as "chronic" when attacks occur for more than one year without a remission period, or with remission lasting less than one month.(5)

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

1. Headache disorders. World Health Organization website. http://www.who.int/mediacentre/factsheets/fs277/en/. Accessed April 5, 2017.
2. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual Review of Pharmacology and Toxicology. 2015;55:533-552.
3. Identifying and treating migraine. American Migraine Foundation website. https://americanmigrainefoundation.org/understanding-migraine/identifying-treating-migraine/. Accessed April 19, 2017.
4. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Prevalence and Prevention study. Headache. 2007;47(3):355-363.
5. Treatment for cluster headache. American Migraine Foundation website. https://americanmigrainefoundation.org/understanding-migraine/treatment-of-cluster-headache/. Accessed April 19, 2017.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...